Job title: Co-Founder
Over 15 years’ experience in a fast-track career, from premier research institutions to co-founding biotech and venture capital firms. Co-founded 5 biotech companies in Europe and the US. Currently, He is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He is also supporting investments and strategic partnerships at Life Biosciences Inc. in Europe. Currently, Marc is a strategic advisor at Ninevah Therapeutics, Cebiotex, Retinset Therapeutics and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. Marc is also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets).
Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.
Immune-mediated Clearance of Senescence Cells in Oncology 9:30 am
Explore targeting an immune-oncology target expressed on senescent cells to develop novel senotherapies Examine the clinical outcome: Improve SOC in the oncology field by eliminating therapy-induced senescence in cancer An exclusive look at Rejuversen’s development of a biological medicineRead more
day: Day Two
Panel Discussion: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities 4:50 pm
Examining what we do and do not know about the aging process Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions Analyzing the current R&D landscape for anti-aging therapeutics Discussing recent breakthroughs and the growing interest in this space – attracting funding/ partnerships, important learnings to date…Read more
day: Day One